本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年10月28 日召开第四届董事会第十三次会议，审议通过了《关于2025年第三季度计提资产 减值准备的议案》，根据《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》《企业会计准则第8号——资产减值》及公司会计政策 等相关规定，公司拟对截至2025年9月30日合并财务报表范围内可能发生减值迹 象的相关资产计提减值准备，该事项在公司董事会审批权限范围内，无需提交公 司股东会审议。现将具体情况公告如下： 一、本次拟计提资产减值准备的情况概述 经公司及下属子公司对截至2025年9月30日可能存在减值迹象的各类资产进行 全面检查和减值测试后，基于谨慎性原则，公司2025年第三季度拟计提信用减值准 备128.70万元，转回信用减值准备127.19万元，计提资产减值准备10,365.33万元，转 回资产减值准备0.48万元，具体明细如下： 单位：万元 | 项目名称 | 2025年6月30日 | 本期变动金额 | | 期末账面余额 | | --- ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-047 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第 十三次会议于 2025 年 10 月 28 日 10:00 在公司会议室以现场结合通讯的方式召 开。本次会议通知已于 2025 年 10 月 24 日通过邮件的方式送达全体董事。本次 会议应出席董事 8 人，实际出席董事 8 人，其中独立董事沈世娟女士、朱旗先生、 上官俊杰先生以通讯方式出席会议。会议由董事长万世平先生召集并主持，公司 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《中华 人民共和国公司法》（以下简称"《公司法》"）等有关法律法规及《公司章程》 的相关规定。 二、董事会会议审议情况 江苏东星智慧医疗科技股份有限公司 第四届董事会第十三次会议决议公告 根据《公司法》等法律法规、规范性文件及《公司章程》的规定，结合公司 实际经营情况，公司编制了《2025 年第三季度报告》。 经审核，董事会认为公司《2025 年第三季度报告 ...

Core Insights - Dongxing Medical reported a third-quarter revenue of 100 million yuan, a year-on-year decrease of 1.97% [1] - The net profit for the third quarter was a loss of 83.4945 million yuan [1] - For the first three quarters, the revenue totaled 284 million yuan, reflecting a year-on-year decline of 10.21% [1] - The net profit for the first three quarters was a loss of 53.2016 million yuan [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥100,445,210.23, representing a decrease of 1.97% compared to the same period last year[5] - The net profit attributable to shareholders was -¥83,494,508.46, a significant decline of 566.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥88,655,148.99, down 834.63% from the previous year[5] - The net profit for the current period is -53,521,791.79, compared to a profit of 65,446,579.46 in the previous period, indicating a significant decline[25] - Operating profit for the current period is -42,533,744.96, down from 78,640,550.02 in the previous period[25] - The company reported a total comprehensive loss of -53,521,791.79 for the current period, compared to a comprehensive income of 65,446,579.46 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,399,532,273.08, a decrease of 3.34% from the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 49,091,596.87 from CNY 295,179,331.27, representing a decline of 83.42%[20] - Total liabilities increased to CNY 258,354,065.39 from CNY 228,880,540.24, an increase of 12.87%[22] - The company's equity attributable to shareholders decreased to CNY 2,132,288,193.82 from CNY 2,246,597,316.84, a decrease of 5.08%[22] - Non-current assets decreased to CNY 940,317,332.02 from CNY 1,058,892,323.48, a decline of 11.16%[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥48,009,972.24, down 43.72% compared to the same period last year[5] - The net cash flow from operating activities is 48,009,972.24, a decrease from 85,301,119.49 in the previous period[26] - Cash received from borrowings increased significantly by 914.16% to ¥111,557,740 from ¥11,000,000, reflecting an increase in bank loans[13] - Cash used for debt repayment surged by 22,735.75% to ¥45,671,492 from ¥200,000, mainly due to increased bank loan repayments[13] - Investment activities resulted in a net cash outflow of -123,932,844.26, compared to -405,944,489.34 in the previous period[27] Expenses and Costs - The company reported a significant increase in financial expenses, totaling ¥499,615.92, an increase of 118.10% due to higher bank loan interest payments[11] - Investment income decreased by 31.95% to ¥18,893,562.47, primarily due to reduced interest from financial products[11] - Total operating costs amounted to CNY 245,520,282.82, down 7.66% from CNY 265,917,172.26 in the previous period[24] Shareholder Information - The total number of shareholders holding ordinary shares is significant, with the largest shareholder holding 25.02% of the shares[16] Development and Strategy - The company has increased its development expenditure by 100% to ¥2,100,000.00, reflecting investment in new product development[10] - The company plans to continue focusing on market expansion and new product development strategies[19] Other Financial Metrics - Basic and diluted earnings per share for the current period are both -0.53, compared to 0.66 in the previous period[26] - The company did not undergo an audit for the third quarter financial report[28]

Group 1 - The core point of the article is that Dongxing Medical (301290) reported a total of 10,933 shareholders as of October 20, 2025, including credit accounts [1]

证券代码：301290 证券简称：东星医疗 公告编号：2025-043 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 2、本次交易存在不确定性，可能出现因外部环境变化导致交易条件发生变化， 进而导致交易终止的情况。敬请广大投资者注意投资风险。 3、根据《上市公司股票停复牌规则》《深圳证券交易所上市公司自律监管指引 第 6 号——停复牌》的相关规定，本次筹划事项公司股票不停牌。公司将根据相关 事项的进展情况，分阶段及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 江苏东星智慧医疗科技股份有限公司董事会 江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝" 或"标的公司"）90%的股权（以下简称"本次交易"），本次交易如能顺利实 施，武汉医佳宝将成为公司的控股子公司。 根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易不涉及上市公司发行股 ...

Core Insights - Dongxing Medical's stock increased by 1.12% on October 10, with a trading volume of 80.51 million yuan [1] - The company experienced a net financing outflow of 5.14 million yuan on the same day, indicating a decrease in investor confidence [1] - As of October 10, the total balance of margin trading for Dongxing Medical was 69.64 million yuan, which is low compared to the past year [1] Financial Performance - For the first half of 2025, Dongxing Medical reported a revenue of 183 million yuan, a year-on-year decrease of 14.17% [2] - The net profit attributable to the parent company was 30.29 million yuan, down 36.47% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amounted to 169 million yuan [3] Shareholder Information - As of September 30, the number of shareholders for Dongxing Medical reached 12,600, an increase of 21.02% from the previous period [2] - The average number of circulating shares per shareholder decreased by 17.37% to 5,409 shares [2] Business Overview - Dongxing Medical specializes in the research, development, production, and sales of surgical medical devices, primarily focusing on staplers [1] - The revenue composition includes staplers (53.03%), stapler accessories (17.55%), medical equipment (15.59%), low-value consumables (13.24%), and others (0.59%) [1]

Core Viewpoint - Dongxing Medical plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd., which is expected to constitute a major asset restructuring, aiming to enhance its product line and performance amid declining revenues and profits [1][5][6] Financial Performance - Dongxing Medical's main business focuses on surgical medical devices, particularly staplers, with stable performance from 2021 to 2024, maintaining revenue between 420 million to 450 million yuan and net profit between 97 million to 120 million yuan [2] - However, the company's non-recurring net profit has been declining, with figures of 103 million, 94.51 million, 68.16 million, and 66.46 million yuan over the same period [2] - In the first half of this year, revenue dropped by 14.17% to 183 million yuan, and net profit fell by 36.47% to 30.29 million yuan, with a significant decline in non-recurring net profit by 37.78% to 19.04 million yuan [2] Product Performance - The gross margins for staplers, medical devices, low-value consumables, and stapler accessories have all decreased, with declines of 1.25%, 6.56%, 0.1%, and 19.14% respectively [2] - Only staplers saw a revenue increase of 7.11%, while the other three product categories experienced revenue declines of 19.57%, 7.05%, and 44.45% [2] Cash Flow and Financial Health - In 2024, the net cash flow from operating activities decreased by 22.46% to 126 million yuan, with a dramatic drop of 69.59% to 21.39 million yuan in the first half of this year due to reduced cash receipts from sales [3] - As of June 30, the company had cash and cash equivalents of 63.23 million yuan, with short-term borrowings increasing to 88.93 million yuan, indicating a tightening cash flow situation [3] Strategic Adjustments - In response to business pressures, Dongxing Medical has initiated a strategic shift by establishing Changzhou Dongxing Biopharmaceutical Co., Ltd. to explore new growth areas in synthetic biology, focusing on recombinant humanized collagen and mussel adhesive proteins [4] - The acquisition of Wuhan Yijiaobao is seen as a critical strategic move to quickly gain mature R&D capabilities and product lines in the high-end orthopedic and biomedical materials market, complementing its existing surgical stapler business [5][6] Acquisition Details - Wuhan Yijiaobao is recognized for its high-end orthopedic and biomedical materials, holding 58 medical device registration certificates across three product lines [5] - The acquisition aims to tap into the rapidly growing medical aesthetics market, leveraging products like recombinant collagen and hyaluronic acid, which have broad applications across various medical fields [5][6] - The final transaction details, including the purchase price, are yet to be disclosed, and the company plans to conduct due diligence with relevant advisors [6]

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

Core Viewpoint - Dongxing Medical (301290.SZ) announced a major asset restructuring plan to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through cash payment, aiming to enhance its strategic business development and expand its orthopedic medical device industry chain [1][3]. Group 1: Acquisition Details - The acquisition agreement was signed on September 26, 2025, but the final terms, including the shareholding ratio and transaction price, are still subject to further negotiation [1][2]. - If the transaction is successfully completed, Wuhan Yijiaobao will become a subsidiary of Dongxing Medical, and the company will hold 90% of its shares [2]. Group 2: Financial Performance - In the first half of 2025, Dongxing Medical reported a revenue of 183 million yuan, a year-on-year decrease of 14.17%, and a net profit attributable to shareholders of 30 million yuan, down 36.47% [3]. - The net cash flow from operating activities was 21 million yuan, reflecting a significant decline of 69.59% year-on-year [3]. Group 3: Goodwill and Financial Risks - As of June 30, 2025, the goodwill on Dongxing Medical's consolidated balance sheet was valued at 533.93 million yuan, primarily arising from acquisitions of other medical companies [4]. - The company conducts annual impairment tests on goodwill, and any adverse changes in market conditions or regulatory policies could lead to significant impairment risks, affecting profitability [4]. Group 4: Historical Financial Trends - Dongxing Medical's net profit attributable to shareholders has been declining for three consecutive years, with figures of 110 million yuan in 2021, 103 million yuan in 2022, and 97 million yuan in 2023 [6]. - The company went public on November 30, 2022, raising a total of 1.1 billion yuan, with net proceeds of approximately 1 billion yuan after expenses [8].